<?xml version="1.0" encoding="UTF-8"?>
<p>Vaccines are the cornerstone in protection against influenza. However, currently used influenza vaccines have limitations and the process of production in eggs is vulnerable. 
 <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmicb.2019.02031" xmlns:xlink="http://www.w3.org/1999/xlink">Yamada et al.</ext-link> report preclinical results on the efficacy of a recombinant hemagglutinin protein vaccine candidate produced in human Expi293F cell culture. Interestingly, recombinant hemagglutinin protein of H1N1pdm09 virus protected mice not only against H1N1pdm09 virus but also against avian H5N1 influenza virus.
</p>
